The Biorepository Core (BioC) complements the services provided by the Pharmacology Core and provides the laboratory-based, epidemiological, and clinical investigators with a diverse selecfion of human fissue specimens necessary for research. A major goal of the Core is to accelerate the transifion from basic science to clinical research by providing access to well characterized human tissue. Within the established rules ofthe Human Invesfigafive Committee and HIPAA, the Core performs several funcfions. These include patient consenfing, tissue collection, tissue processing, banking and storage, retrieval, and transfer of fresh frozen and formalin fixed paraffin embedded human tissue obtained from the surgical suites and endoscopic units of KCI. Key services include case identification by diagnostic categories and subsequent retrieval of pathology materials (reports, blocks, slides, banked fixed and frozen materials), providing complete and accurate pathological diagnosis and interpretafions.
; BioC services enable basic science, population science, and clinical researchers to expand further into translational research. This is accomplished by the Core providing unique malignant and benign focused tissues from its tissue bank. Additionally, KCI investigators are able to use the BioC to rapidly evaluate targets and biomarkers relevant to cancer cure. Tissues acquired through this Core come from a diverse population, aiding research into health disparities.
|Ratanatharathorn, V; Deol, A; Ayash, L et al. (2015) Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT. Bone Marrow Transplant 50:106-12|
|Bollig-Fischer, Aliccia; Chen, Wei; Gadgeel, Shirish M et al. (2015) Racial diversity of actionable mutations in non-small cell lung cancer. J Thorac Oncol 10:250-5|
|Motzer, Robert J; Rini, Brian I; McDermott, David F et al. (2015) Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol 33:1430-7|
|Wijesinghe, Priyanga; Bepler, Gerold; Bollig-Fischer, Aliccia (2015) A mass spectrometry assay to simultaneously analyze ROS1 and RET fusion gene expression in non-small-cell lung cancer. J Thorac Oncol 10:381-6|
|Koo, Imhoi; Yao, Sen; Zhang, Xiang et al. (2014) Comparative analysis of false discovery rate methods in constructing metabolic association networks. J Bioinform Comput Biol 12:1450018|
|Koo, Imhoi; Wei, Xiaoli; Shi, Xue et al. (2014) Constructing Metabolic Association Networks Using High-dimensional Mass Spectrometry Data. Chemometr Intell Lab Syst 138:193-202|
|Heng, D Y C; Choueiri, T K; Rini, B I et al. (2014) Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol 25:149-54|
|Szalai, Gabor; Xu, Yi; Romero, Roberto et al. (2014) In vivo experiments reveal the good, the bad and the ugly faces of sFlt-1 in pregnancy. PLoS One 9:e110867|
|Bengsch, F; Buck, A; Gunther, S C et al. (2014) Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression. Oncogene 33:4474-84|
|Speyer, Cecilia L; Hachem, Ali H; Assi, Ali A et al. (2014) Metabotropic glutamate receptor-1 as a novel target for the antiangiogenic treatment of breast cancer. PLoS One 9:e88830|
Showing the most recent 10 out of 321 publications